Table 1 Patient characteristics.
From: Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients
Clinical variables | Patients (n = 64) |
|---|---|
Age (years), median [range] | 64.9 [41.2–83.2] |
Gender (male) | 37 (58%) |
T | |
1 | 15 (23%) |
2 | 10 (16%) |
3 | 37 (58%) |
4 | 2 (3%) |
N | |
0 | 47 (73%) |
1 | 17 (27%) |
M | |
0 | 34 (53%) |
1 | 30 (47%) |
Stage | |
1 | 8 (13%) |
2 | 9 (14%) |
3 | 16 (25%) |
4 | 31 (48%) |
Fuhrman grade | |
1 | 4 (6%) |
2 | 24 (39%) |
3 | 29 (45%) |
4 | 6 (9%) |
Mortality in 5 years | 36 (56%) |
Sunitinib response (RECIST criteria) | |
Partial response | 17 (27%) |
Stable disease | 35 (55%) |
Progressive disease | 6 (9%) |
Not defined | 6 (9%) |
Sunitinib treatment time (days), median [range] | 255 [13–2028] |
Sunitinib dosage | |
25 mg | 17 (27%) |
37 mg | 31 (48%) |
50 mg | 16 (25%) |
Sunitinib dose reduction | 31 (48%) |
Sunitinib dose escalation | 22 (34%) |
Progression-free survival events | |
Treatment failure | 32 (43%) |
Censored, end of follow-up | 13 (18%) |
Censored, side effects | 18 (24%) |
Censored, request by the patient | 1 (1%) |
Treatment prior to sunitinib | |
Targeted therapy | 0 (0%) |
Interferon-α | 9 (14%) |
MSKCC risk class | |
Low | 14 (22%) |
Intermediate | 43 (67%) |
High | 7 (11%) |
